US 11,730,734 B2
Use of ATR and Chk1 inhibitor compounds
Christopher Fisher, Gainesville, FL (US); Terri G. Edwards, Gainesville, FL (US); and David C. Bloom, Gainesville, FL (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Appl. No. 16/332,211
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
PCT Filed Sep. 12, 2017, PCT No. PCT/US2017/051176
§ 371(c)(1), (2) Date Mar. 11, 2019,
PCT Pub. No. WO2018/049400, PCT Pub. Date Mar. 15, 2018.
Claims priority of provisional application 62/393,166, filed on Sep. 12, 2016.
Prior Publication US 2019/0269682 A1, Sep. 5, 2019
Int. Cl. A61K 31/4965 (2006.01); A61P 31/22 (2006.01); A61K 31/439 (2006.01); A61K 31/497 (2006.01); A61K 31/5377 (2006.01); A61K 31/5517 (2006.01); A61K 31/505 (2006.01); A61K 31/4745 (2006.01); A61K 31/5355 (2006.01); A61K 31/4709 (2006.01); A61K 45/06 (2006.01); A61K 31/36 (2006.01)
CPC A61K 31/4965 (2013.01) [A61K 31/36 (2013.01); A61K 31/439 (2013.01); A61K 31/4709 (2013.01); A61K 31/4745 (2013.01); A61K 31/497 (2013.01); A61K 31/505 (2013.01); A61K 31/5355 (2013.01); A61K 31/5377 (2013.01); A61K 31/5517 (2013.01); A61K 45/06 (2013.01); A61P 31/22 (2018.01)] 10 Claims
 
1. A method of treating or preventing a herpesvirus infection in a subject comprising administering to the subject identified as in need thereof VE-822:

OG Complex Work Unit Chemistry
or salt, hydrate or solvate thereof.